These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20959525)

  • 1. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects.
    Lasseter KC; Aubets J; Chuecos F; Gil EG
    J Clin Pharmacol; 2011 Jun; 51(6):923-32. PubMed ID: 20959525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.
    Jansat JM; Lamarca R; de Miquel G; Schrödter A; Miletzki B; Gurniak M
    J Clin Pharmacol; 2009 Oct; 49(10):1239-46. PubMed ID: 19592595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.
    Ortiz S; Flach S; Caracta C; Gil EG; Jansat JM
    J Clin Pharmacol; 2012 Jun; 52(6):819-27. PubMed ID: 21628603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
    Wang Z; Grasela DM; Krishna G
    Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.
    Joos GF; Schelfhout VJ; Pauwels RA; Kanniess F; Magnussen H; Lamarca R; Jansat JM; Garcia Gil E
    Respir Med; 2010 Jun; 104(6):865-72. PubMed ID: 20044242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.
    Jansat JM; Lamarca R; Garcia Gil E; Ferrer P
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):460-8. PubMed ID: 19640353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
    Lasseter K; Dilzer S; Jansat JM; Garcia Gil E; Caracta CF; Ortiz S
    Pulm Pharmacol Ther; 2012 Apr; 25(2):193-9. PubMed ID: 22366196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study.
    Drollmann A; Sechaud R; Pal P; Hara H; Uziel-Fusi S; Winkle P
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):739-45. PubMed ID: 24986094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.
    Mansbach RS; Ludington E; Rogowski R; Kittrelle JP; Jochelson P
    Clin Ther; 2011 Jul; 33(7):851-62. PubMed ID: 21722958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals.
    March B; Cardi T
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1807-15. PubMed ID: 19938897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial.
    Schmid K; Pascual S; Gil EG; Ortiz S; Jansat JM
    Clin Ther; 2010 Sep; 32(10):1798-812. PubMed ID: 21194604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹⁴C]-aclidinium bromide in healthy subjects.
    Ortiz S; Flach S; Ho J; Li F; Caracta CF; Gil EG; Jansat JM
    Biopharm Drug Dispos; 2012 Jan; 33(1):39-45. PubMed ID: 22275272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
    Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
    Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
    Kori S; Kellerman DJ; Voloshko P; Haugen G
    Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
    Hug B; Abbas R; Leister C; Burns J; Sonnichsen D
    Clin Cancer Res; 2010 Aug; 16(15):4016-23. PubMed ID: 20647478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil.
    Fossa AA; Langdon G; Couderc JP; Zhou M; Darpo B; Wilson F; Wallis R; Davis JD
    Clin Pharmacol Ther; 2011 Sep; 90(3):449-54. PubMed ID: 21814193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.